Curis inc.-CRIS
- Creatore Discussione tremaui
- Data di inizio
-
ANNUNCIO: Segui le NewsLetter di Borse.it.
Al via la Newsletter di Borse, con tutte le notizie quotidiane sui mercati finanziari. Iscriviti per rimanere aggiornato con le ultime News di settore, quotazioni e titoli del momento.
Per iscriverti visita questo link.
Zantrax
BOILER ROOM
- Registrato
- 3/9/03
- Messaggi
- 4.151
- Punti reazioni
- 166
Scritto da tremaui
..no nulla di particolare il titolo è sotto copertura al momento e sembra che 5$ sia un bel scalino da cui partire io ho preso posizione su questa quota vediamo un pò che succede
OK
ANCHE SE A GUARDARE IL GRAFICO SOPRA
SEMBRA CHE DOPO OGNI PICCO DI VOLUMI IL TITOLO ABBIA STORNATO
I SOLITI GIOCHINI DEL TIRA E MOLLA...............
STI BAMBINONI DI "SQUALI IN GIACCA E CRAVATTA", NON SMETTONO MAI DI GIOCARE
PalmBeach
IL MONDO KE VORREI!!
- Registrato
- 16/7/03
- Messaggi
- 2.194
- Punti reazioni
- 228
Scritto da ffaiper
azzzzzzz mr e pensare ke quei 6 dollari fino a ieri sembravano un miraggio,,,,,siamo gia a meta stada,,piu una corsia avanti
piano piano ci avviciniamo,,,,
anke oggi un bel goooooooooooooooo
grazie Trmx,,,,,,
tremaui
KA MATE KA ORA!!
- Registrato
- 26/8/00
- Messaggi
- 2.325
- Punti reazioni
- 109
5F: CRIS: Potential Alternative Treatment Should Not Affect BCC Market Opportuni [DFVPSFN]
11:00am EST 5-Mar-04 Brean Murray & Co. (Jonathan Aschoff PhD 212-702-6) CRIS
Curis, Inc. (CRIS-$5.65-Strong Buy) 3/05/04
---------------------------------------------------------------------------
Potential alternative treatment for BCC from 3M Pharmaceuticals, Inc. should not
affect the market opportunity for CRIS's Hh antagonist program
Yesterday, 3M Pharmaceuticals, Inc. announced FDA approval of AldaraTM, an
immune response modifier, for the treatment of Actinic Keratosis (AK), and
AldaraTM is under FDA review for the treatment of superficial BCC (sBCC), which
makes up about 80% of BCC population.
?3M's proposed AldaraTM treatment for sBCC is a topical application, similar to
CRIS's Hh antagonist program; however, the mechanism of action is vastly
different.
AldaraTM efficacy data, where approximately 80% of patients showed complete sBCC
clearance rate, is lower than that of surgery, the current standard of
treatment.
We reiterate our Strong Buy rating and our $9.00 one-year target.
===========================================================================
52-Week Market Est EPS Cash/ Qtr Burn Ent. Target Risk
Range Cap Growth 03 Rate Value Price Profile
$7-0.65 $233.7M NM $37.7M $3.9M $218M $9.00 High
---------------------------------------------------------------------------
EPS Q1 Q2 Q3 Q4 Total P/E Cons.
12/02A (2.57) NM
12/03A (0.14) (0.15) 0.11 (0.17) (0.33) NM
12/04E (0.11) (0.11) (0.11) (0.06) (0.39) NM (0.39)
12/05E (0.15) NM (0.15)
12/06E (0.22) NM (0.22)
===========================================================================
Yesterday, 3M Pharmaceuticals, Inc. announced FDA approval of AldaraTM, an
immune response modifier, for the treatment of Actinic Keratosis (AK), and
AldaraTM is under FDA review for the treatment of superficial BCC (sBCC), which
makes up about 80% of BCC population. Actinic keratosis are lesions on the
outermost layer of the skin and are typically precursors to skin cancer. AK
affects approximately 10 million patients, mostly as a result of chronic sun
exposure.
3M's proposed AldaraTM treatment for sBCC is a topical application, similar to
CRIS's Hh antagonist program; however, the mechanism of action is vastly
different. AldaraTM works by inducing the production of cytokines to start a
strong immune reaction to eliminate virus infected cells and tumor cells.
However, given the strong immune response to the targeted site, many patients
experience side-effects including rash and inflammation during the treatment
period (12 weeks for the AldaraTM pivotal study.) CRIS's Hh antagonist program
works by inhibiting the over-expression of the Hh pathway, which is believed to
be the main underlying cause of BCC. In pre-clinical studies, no toxicity was
observed.
AldaraTM efficacy data, where approximately 80% of patients showed complete sBCC
clearance rate, is lower than that of surgery, the current standard of
treatment. Although BCC is highly curable, recurrence rates and side-effects
are major concerns. We believe that CRIS's Hh antagonist program, although
still years from NDA submission, will be the standard of care, if approved.
We reiterate our Strong Buy rating and our $9.00 one-year target.
===========================================================================
IMPORTANT DISCLOSURES
Stock price charts designating rating change/target price information are
available upon request. Please contact shriverj@bmur.com.
Strong Buy: Expected to significantly outperform market*
32.9% of universe Low to moderate risk to fundamentals or valuation
34.8% IB clients Immediacy of story: 6 to 12 months
Buy: Expected to moderately outperform market*;
47.1% of universe Moderate risk to fundamentals or valuation
15.2% IB clients OR Expected to significantly outperform market*;
High risk to fundamentals or valuation
Immediacy of story: 12 months
Neutral: Expected to perform in line with market*
15.7% of universe OR Analyst lacks the conviction to recommend purchase
18.2% IB clients or sale of this security
Low, moderate or high risk to fundamentals/valuation
Immediacy of story: 6 to 12 months
Underperform: Expected to moderately underperform market*
1.4% of universe Low, moderate or high risk to fundamentals/valuation
0.0% IB clients Immediacy of story: 12 months
Sell: Expected to significantly underperform market*
0.0% of universe High risk to fundamentals or valuation
0.0% IB clients Immediacy of story: 6 to 12 months
* Relative to S&P 500 for larger capitalization stocks; Russell 2000 for medium
and small caps.
Brean Murray & Co., Inc. makes a market in CRIS.
The securities discussed in Brean Murray & Co., Inc research reports may not be
suitable for some investors. Emerging growth companies, in particular, offer a
high degree of risk. Investors must make their own determination as to the
appropriateness of an investment in any securities referred to herein, based on
their specific investment objectives, financial status and risk tolerance. The
research analysts responsible for the preparation of this report have received
compensation based upon various factors, including quality of research, investor
client feedback, stock picking, and firm revenues. The views expressed in this
report accurately reflect the individual analyst's views about the subject
company. No part of the individual analysts compensation was, is, or will be
directly or indirectly tied to the specific recommendations or views contained
within this research report. In the next three months, Brean Murray & Co., Inc.
expects to receive or intends to seek compensation for investment banking
services from the issuer of these securities.
Additional information is available on request.
Brean Murray & Co, Inc. (the "Firm") is a member of the New York Stock Exchange,
Inc. and other principal exchanges and a registered U.S. Broker-Dealer. Readers
are advised that this analysis report is issued solely for informational
purposes and is not to be construed as an offer to sell or the solicitation of
an offer to buy. The information contained herein is based on sources which we
believe to be reliable but is not guaranteed by us as being accurate and does
not purport to be a complete statement or summary of the available data. Past
performance is no guarantee of future results. Any opinions expressed herein are
statements of our judgment as of the date of publication and are subject to
change without notice. Reproduction without written permission is prohibited.
Entities including but not limited to the Firm, its officers, directors,
employees, customers, affiliates may have a position, long or short, in the
securities referred to herein, and/or other related securities, and from time to
time may increase or decrease such position or take a contra position. The Firm
(or persons related thereto) may make a market in the securities mentioned
herein, and may from time to time perform investment banking or other services
for, or solicit investment banking or other business from, and may have other
relationships with any company mentioned in this report. Member SIPC.
Additional information is available to clients upon request.
First Call Corporation, a Thomson Financial company.
All rights reserved. 888.558.2500
05mar04 15:59 GMT
Symbols:
US;CRIS DE;CUS
11:00am EST 5-Mar-04 Brean Murray & Co. (Jonathan Aschoff PhD 212-702-6) CRIS
Curis, Inc. (CRIS-$5.65-Strong Buy) 3/05/04
---------------------------------------------------------------------------
Potential alternative treatment for BCC from 3M Pharmaceuticals, Inc. should not
affect the market opportunity for CRIS's Hh antagonist program
Yesterday, 3M Pharmaceuticals, Inc. announced FDA approval of AldaraTM, an
immune response modifier, for the treatment of Actinic Keratosis (AK), and
AldaraTM is under FDA review for the treatment of superficial BCC (sBCC), which
makes up about 80% of BCC population.
?3M's proposed AldaraTM treatment for sBCC is a topical application, similar to
CRIS's Hh antagonist program; however, the mechanism of action is vastly
different.
AldaraTM efficacy data, where approximately 80% of patients showed complete sBCC
clearance rate, is lower than that of surgery, the current standard of
treatment.
We reiterate our Strong Buy rating and our $9.00 one-year target.
===========================================================================
52-Week Market Est EPS Cash/ Qtr Burn Ent. Target Risk
Range Cap Growth 03 Rate Value Price Profile
$7-0.65 $233.7M NM $37.7M $3.9M $218M $9.00 High
---------------------------------------------------------------------------
EPS Q1 Q2 Q3 Q4 Total P/E Cons.
12/02A (2.57) NM
12/03A (0.14) (0.15) 0.11 (0.17) (0.33) NM
12/04E (0.11) (0.11) (0.11) (0.06) (0.39) NM (0.39)
12/05E (0.15) NM (0.15)
12/06E (0.22) NM (0.22)
===========================================================================
Yesterday, 3M Pharmaceuticals, Inc. announced FDA approval of AldaraTM, an
immune response modifier, for the treatment of Actinic Keratosis (AK), and
AldaraTM is under FDA review for the treatment of superficial BCC (sBCC), which
makes up about 80% of BCC population. Actinic keratosis are lesions on the
outermost layer of the skin and are typically precursors to skin cancer. AK
affects approximately 10 million patients, mostly as a result of chronic sun
exposure.
3M's proposed AldaraTM treatment for sBCC is a topical application, similar to
CRIS's Hh antagonist program; however, the mechanism of action is vastly
different. AldaraTM works by inducing the production of cytokines to start a
strong immune reaction to eliminate virus infected cells and tumor cells.
However, given the strong immune response to the targeted site, many patients
experience side-effects including rash and inflammation during the treatment
period (12 weeks for the AldaraTM pivotal study.) CRIS's Hh antagonist program
works by inhibiting the over-expression of the Hh pathway, which is believed to
be the main underlying cause of BCC. In pre-clinical studies, no toxicity was
observed.
AldaraTM efficacy data, where approximately 80% of patients showed complete sBCC
clearance rate, is lower than that of surgery, the current standard of
treatment. Although BCC is highly curable, recurrence rates and side-effects
are major concerns. We believe that CRIS's Hh antagonist program, although
still years from NDA submission, will be the standard of care, if approved.
We reiterate our Strong Buy rating and our $9.00 one-year target.
===========================================================================
IMPORTANT DISCLOSURES
Stock price charts designating rating change/target price information are
available upon request. Please contact shriverj@bmur.com.
Strong Buy: Expected to significantly outperform market*
32.9% of universe Low to moderate risk to fundamentals or valuation
34.8% IB clients Immediacy of story: 6 to 12 months
Buy: Expected to moderately outperform market*;
47.1% of universe Moderate risk to fundamentals or valuation
15.2% IB clients OR Expected to significantly outperform market*;
High risk to fundamentals or valuation
Immediacy of story: 12 months
Neutral: Expected to perform in line with market*
15.7% of universe OR Analyst lacks the conviction to recommend purchase
18.2% IB clients or sale of this security
Low, moderate or high risk to fundamentals/valuation
Immediacy of story: 6 to 12 months
Underperform: Expected to moderately underperform market*
1.4% of universe Low, moderate or high risk to fundamentals/valuation
0.0% IB clients Immediacy of story: 12 months
Sell: Expected to significantly underperform market*
0.0% of universe High risk to fundamentals or valuation
0.0% IB clients Immediacy of story: 6 to 12 months
* Relative to S&P 500 for larger capitalization stocks; Russell 2000 for medium
and small caps.
Brean Murray & Co., Inc. makes a market in CRIS.
The securities discussed in Brean Murray & Co., Inc research reports may not be
suitable for some investors. Emerging growth companies, in particular, offer a
high degree of risk. Investors must make their own determination as to the
appropriateness of an investment in any securities referred to herein, based on
their specific investment objectives, financial status and risk tolerance. The
research analysts responsible for the preparation of this report have received
compensation based upon various factors, including quality of research, investor
client feedback, stock picking, and firm revenues. The views expressed in this
report accurately reflect the individual analyst's views about the subject
company. No part of the individual analysts compensation was, is, or will be
directly or indirectly tied to the specific recommendations or views contained
within this research report. In the next three months, Brean Murray & Co., Inc.
expects to receive or intends to seek compensation for investment banking
services from the issuer of these securities.
Additional information is available on request.
Brean Murray & Co, Inc. (the "Firm") is a member of the New York Stock Exchange,
Inc. and other principal exchanges and a registered U.S. Broker-Dealer. Readers
are advised that this analysis report is issued solely for informational
purposes and is not to be construed as an offer to sell or the solicitation of
an offer to buy. The information contained herein is based on sources which we
believe to be reliable but is not guaranteed by us as being accurate and does
not purport to be a complete statement or summary of the available data. Past
performance is no guarantee of future results. Any opinions expressed herein are
statements of our judgment as of the date of publication and are subject to
change without notice. Reproduction without written permission is prohibited.
Entities including but not limited to the Firm, its officers, directors,
employees, customers, affiliates may have a position, long or short, in the
securities referred to herein, and/or other related securities, and from time to
time may increase or decrease such position or take a contra position. The Firm
(or persons related thereto) may make a market in the securities mentioned
herein, and may from time to time perform investment banking or other services
for, or solicit investment banking or other business from, and may have other
relationships with any company mentioned in this report. Member SIPC.
Additional information is available to clients upon request.
First Call Corporation, a Thomson Financial company.
All rights reserved. 888.558.2500
05mar04 15:59 GMT
Symbols:
US;CRIS DE;CUS
For several years, Curis has been evaluating the potential of using adult derived stem cells as a potential therapy to treat diabetes. Curis has been successful in demonstrating the "rescue" of diabetic animals using proprietary methods that convert adult stem cells into insulin-producing cells. During 2002, the Company decided that this program would have its best opportunity for success by partnering with a company that is specialized in the development of stem cell based therapeutics.
In December 2002, Curis assigned and licensed its patent rights related to the development of cellular therapeutics for the treatment of diabetes to ES Cell International Pte Ltd (ESI). ESI is a Singapore-based company that develops stem cells as therapeutic products for various human disorders. As part of the overall transaction, ESI will assume all responsibility for future development and clinical testing of Curis' diabetes stem-cell technologies (see press release in news section).
The patent rights provided by Curis to ESI consist of adult-derived progenitor/stem cell compositions of matter, fields of medical use, and progenitor/stem cell related methodologies to transform those stem cells into insulin-producing cells and other cell types important in the treatment of diabetes. Curis received an equity position in ESI in exchange for these technologies and a $1.5 million payment to cover the cost of Curis employees working on the project.
STRATEGIC PARTNER
Molto interessante
In December 2002, Curis assigned and licensed its patent rights related to the development of cellular therapeutics for the treatment of diabetes to ES Cell International Pte Ltd (ESI). ESI is a Singapore-based company that develops stem cells as therapeutic products for various human disorders. As part of the overall transaction, ESI will assume all responsibility for future development and clinical testing of Curis' diabetes stem-cell technologies (see press release in news section).
The patent rights provided by Curis to ESI consist of adult-derived progenitor/stem cell compositions of matter, fields of medical use, and progenitor/stem cell related methodologies to transform those stem cells into insulin-producing cells and other cell types important in the treatment of diabetes. Curis received an equity position in ESI in exchange for these technologies and a $1.5 million payment to cover the cost of Curis employees working on the project.
STRATEGIC PARTNER
Molto interessante
ed ecco il farmaco, che potrebbe garantire la rinascita di una fluente chioma(così è successo con i test svolti su animali)
Several years ago, scientists at Curis showed that Hedgehog (Hh) protein when implanted under the skin of an animal could stimulate rapid hair regrowth. More recently, other researchers have shown that the Hh gene when delivered with a virus can stimulate rapid hair regrowth in animals that had lost hair due to chemotherapy treatment. An abstract of the scientific publication describing this work can be viewed on the PubMed web site of National Institutes of Health
Curis believes that the Hh small molecule agonists (described elsewhere in this website) provide an ideal means of exploiting the hair regrowth properties of the hedgehog pathway for the successful development of a product to treat age induced hair loss (alopecia) or chemotherapy-induced alopecia. Scientists at Curis have recently demonstrated that the Company's small molecule Hh agonists can induce hair regrowth in an animal model.
Curis is currently evaluating the therapeutic potential of small molecule Hh agonists to promote hair regrowth in other models of hair loss, including age-induced and chemotherapy-induced alopecia.
PROPRIETARY
PRODUCT DEVEOPMENT
CURIS Hedgehog Small Molecule
)Several years ago, scientists at Curis showed that Hedgehog (Hh) protein when implanted under the skin of an animal could stimulate rapid hair regrowth. More recently, other researchers have shown that the Hh gene when delivered with a virus can stimulate rapid hair regrowth in animals that had lost hair due to chemotherapy treatment. An abstract of the scientific publication describing this work can be viewed on the PubMed web site of National Institutes of Health
Curis believes that the Hh small molecule agonists (described elsewhere in this website) provide an ideal means of exploiting the hair regrowth properties of the hedgehog pathway for the successful development of a product to treat age induced hair loss (alopecia) or chemotherapy-induced alopecia. Scientists at Curis have recently demonstrated that the Company's small molecule Hh agonists can induce hair regrowth in an animal model.
Curis is currently evaluating the therapeutic potential of small molecule Hh agonists to promote hair regrowth in other models of hair loss, including age-induced and chemotherapy-induced alopecia.
PROPRIETARY
PRODUCT DEVEOPMENT
CURIS Hedgehog Small Molecule
PalmBeach
IL MONDO KE VORREI!!
- Registrato
- 16/7/03
- Messaggi
- 2.194
- Punti reazioni
- 228
Curis to Present at Sachs-Bloomberg 3rd Annual Global Biotech Forum for Investing and Partnering
Tuesday, March 30, 2004 09:14 AM ET
CAMBRIDGE, Mass.--(BUSINESS WIRE)--March 30, 2004--Curis, Inc. (NASDAQ: CRIS, news) announced today that Daniel Passeri, Curis' President and Chief Executive Officer, will speak at the upcoming Sachs-Bloomberg 3rd Annual Global Biotech Forum for Investing and Partnering to be held at the Fairmont Copley Plaza in Boston on April 1-2, 2004. Mr. Passeri's presentation is scheduled for 11:50 AM on Thursday, April 1, where he will present an update on Curis' business model and a review of its therapeutic product development programs. The presentation will be recorded and available on the LifeSciChannel (http://www.lifescichannel.com) after the conference.
The Sachs-Bloomberg conferences are run in major financial centers and focus on emerging growth markets. There are two Biotechnology Forums held annually, in Munich in November and in Boston in April. A selected audience of approximately 400 pharmaceutical companies, emerging biotechnology companies, and investors is invited.
Tuesday, March 30, 2004 09:14 AM ET
CAMBRIDGE, Mass.--(BUSINESS WIRE)--March 30, 2004--Curis, Inc. (NASDAQ: CRIS, news) announced today that Daniel Passeri, Curis' President and Chief Executive Officer, will speak at the upcoming Sachs-Bloomberg 3rd Annual Global Biotech Forum for Investing and Partnering to be held at the Fairmont Copley Plaza in Boston on April 1-2, 2004. Mr. Passeri's presentation is scheduled for 11:50 AM on Thursday, April 1, where he will present an update on Curis' business model and a review of its therapeutic product development programs. The presentation will be recorded and available on the LifeSciChannel (http://www.lifescichannel.com) after the conference.
The Sachs-Bloomberg conferences are run in major financial centers and focus on emerging growth markets. There are two Biotechnology Forums held annually, in Munich in November and in Boston in April. A selected audience of approximately 400 pharmaceutical companies, emerging biotechnology companies, and investors is invited.
